Cytokinetics Inc (CYTK) stock
CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
$51.65−1.52 (-2.86%)
Close on Nov 17, 2026Market cap $7.18BP/E –Yield –
Cytokinetics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Cytokinetics's operating cash flow for the twelve months ending Jun 30, 2026 was -$555.45M. For fiscal 2025 it was -$510.01M. The highest annual figure on record is $36.98M in fiscal 2016.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$510.01M | – |
| FY2024 | Dec 31, 2024 | -$395.89M | – |
| FY2023 | Dec 31, 2023 | -$414.33M | – |
| FY2022 | Dec 31, 2022 | -$299.52M | – |
| FY2021 | Dec 31, 2021 | -$142.52M | -1693.7% |
| FY2020 | Dec 31, 2020 | $8.94M | – |
| FY2019 | Dec 31, 2019 | -$90.91M | – |
| FY2018 | Dec 31, 2018 | -$101.22M | – |
| FY2017 | Dec 31, 2017 | -$101.76M | -375.2% |
| FY2016 | Dec 31, 2016 | $36.98M | +657.4% |
| FY2015 | Dec 31, 2015 | $4.88M | – |
| FY2014 | Dec 31, 2014 | -$44.84M | – |
| FY2013 | Dec 31, 2013 | -$7.72M | – |
| FY2012 | Dec 31, 2012 | -$33.44M | – |
| FY2011 | Dec 31, 2011 | -$45.60M | – |
| FY2010 | Dec 31, 2010 | -$44.83M | -632.7% |
| FY2009 | Dec 31, 2009 | $8.42M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$159.84M | – |
| Q1 FY2026 | Mar 31, 2026 | -$145.46M | – |
| Q4 FY2025 | Dec 31, 2025 | -$142.65M | – |
| Q3 FY2025 | Sep 30, 2025 | -$107.51M | – |
| Q2 FY2025 | Jun 30, 2025 | -$128.24M | – |
| Q1 FY2025 | Mar 31, 2025 | -$131.62M | – |
| Q4 FY2024 | Dec 31, 2024 | -$65.57M | – |
| Q3 FY2024 | Sep 30, 2024 | -$101.50M | – |
| Q2 FY2024 | Jun 30, 2024 | -$99.31M | – |
| Q1 FY2024 | Mar 31, 2024 | -$129.51M | – |
| Q4 FY2023 | Dec 31, 2023 | -$74.04M | – |
| Q3 FY2023 | Sep 30, 2023 | -$96.21M | – |
| Q2 FY2023 | Jun 30, 2023 | -$121.81M | – |
| Q1 FY2023 | Mar 31, 2023 | -$122.29M | – |
| Q4 FY2022 | Dec 31, 2022 | -$98.19M | – |
| Q3 FY2022 | Sep 30, 2022 | -$84.04M | – |
| Q2 FY2022 | Jun 30, 2022 | -$90.48M | – |
| Q1 FY2022 | Mar 31, 2022 | -$26.81M | – |
| Q4 FY2021 | Dec 31, 2021 | -$44.74M | -185.8% |
| Q3 FY2021 | Sep 30, 2021 | -$38.77M | -369.9% |
| Q2 FY2021 | Jun 30, 2021 | -$29.50M | – |
| Q1 FY2021 | Mar 31, 2021 | -$29.52M | – |
| Q4 FY2020 | Dec 31, 2020 | $52.15M | – |
| Q3 FY2020 | Sep 30, 2020 | $14.37M | – |
| Q2 FY2020 | Jun 30, 2020 | -$27.44M | – |
| Q1 FY2020 | Mar 31, 2020 | -$30.14M | – |
| Q4 FY2019 | Dec 31, 2019 | -$19.06M | – |
| Q3 FY2019 | Sep 30, 2019 | -$20.27M | – |
| Q2 FY2019 | Jun 30, 2019 | -$24.68M | – |
| Q1 FY2019 | Mar 31, 2019 | -$26.91M | – |
| Q4 FY2018 | Dec 31, 2018 | -$12.33M | – |
| Q3 FY2018 | Sep 30, 2018 | -$32.24M | – |
| Q2 FY2018 | Jun 30, 2018 | -$26.85M | – |
| Q1 FY2018 | Mar 31, 2018 | -$29.81M | – |
| Q4 FY2017 | Dec 31, 2017 | -$24.07M | -130.9% |
| Q3 FY2017 | Sep 30, 2017 | -$25.48M | – |
| Q2 FY2017 | Jun 30, 2017 | -$31.26M | – |
| Q1 FY2017 | Mar 31, 2017 | -$20.94M | – |
| Q4 FY2016 | Dec 31, 2016 | $77.83M | – |
| Q3 FY2016 | Sep 30, 2016 | -$12.12M | – |
See a number that looks wrong?